AEON Biopharma (AEON) vs Citius Pharmaceuticals (CTXR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed AEON Biopharma (AEON) over the past year, losing 61.0% versus a loss of 73.2%. AEON Biopharma is the larger company by market cap ($13.8 million vs $13.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | CTXR |
|---|---|---|
| Share price | $0.276 | $0.4994 |
| Market cap | $13.77M | $13.71M |
| 1-day change | -10.97% | +2.19% |
| YTD return | -74.91% | -35.73% |
| 1-year return | -73.20% | -60.98% |
| 5-year return | — | -99.04% |
| EPS (TTM) | $-3.91 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.45 | $2.19 |
| 52-week low | $0.177 | $0.469 |
| Distance from 52-week high | -80.97% | -77.20% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +559.42% | +700.96% |
| Average volume | 8.73M | 535.02K |
| Shares outstanding | 49.88M | 27.45M |
| Employees | 8 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed AEON by 12.2 percentage points over the past year.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
AEON vs CTXR FAQ
Which is bigger, AEON Biopharma or Citius Pharmaceuticals?
AEON Biopharma (AEON) is larger, with a market capitalization of $13.77M compared with $13.71M for Citius Pharmaceuticals (CTXR).
Which stock has performed better over the past year, AEON or CTXR?
CTXR returned -60.98% over the past 12 months, compared with -73.20% for AEON (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and Citius Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.